BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 28574509)

  • 21. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.
    Leprivier G; Remke M; Rotblat B; Dubuc A; Mateo AR; Kool M; Agnihotri S; El-Naggar A; Yu B; Somasekharan SP; Faubert B; Bridon G; Tognon CE; Mathers J; Thomas R; Li A; Barokas A; Kwok B; Bowden M; Smith S; Wu X; Korshunov A; Hielscher T; Northcott PA; Galpin JD; Ahern CA; Wang Y; McCabe MG; Collins VP; Jones RG; Pollak M; Delattre O; Gleave ME; Jan E; Pfister SM; Proud CG; Derry WB; Taylor MD; Sorensen PH
    Cell; 2013 May; 153(5):1064-79. PubMed ID: 23706743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
    Tao L; Mohammad MA; Milazzo G; Moreno-Smith M; Patel TD; Zorman B; Badachhape A; Hernandez BE; Wolf AB; Zeng Z; Foster JH; Aloisi S; Sumazin P; Zu Y; Hicks J; Ghaghada KB; Putluri N; Perini G; Coarfa C; Barbieri E
    Nat Commun; 2022 Jun; 13(1):3728. PubMed ID: 35764645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
    Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
    J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
    Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
    Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.
    Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C
    Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504
    [No Abstract]   [Full Text] [Related]  

  • 27. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
    Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
    Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.
    Gu L; Chu P; Lingeman R; McDaniel H; Kechichian S; Hickey RJ; Liu Z; Yuan YC; Sandoval JA; Fields GB; Malkas LH
    EBioMedicine; 2015 Dec; 2(12):1923-31. PubMed ID: 26844271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
    Zins K; Kovatchki D; Lucas T; Abraham D
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA N
    Cheng J; Xu L; Deng L; Xue L; Meng Q; Wei F; Wang J
    Sci Rep; 2020 Aug; 10(1):13624. PubMed ID: 32788584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MYCN 5' UTR as a therapeutic target in neuroblastoma.
    Volegova MP; Brown LE; Banerjee U; Dries R; Sharma B; Kennedy A; Porco JA; George RE
    Cell Rep; 2024 May; 43(5):114134. PubMed ID: 38662542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma.
    Lu Y; Yang Q; Su Y; Ji Y; Li G; Yang X; Xu L; Lu Z; Dong J; Wu Y; Bei JX; Pan C; Gu X; Li B
    Cell Death Dis; 2021 May; 12(6):511. PubMed ID: 34011924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.
    Ambrosio S; Amente S; Saccà CD; Capasso M; Calogero RA; Lania L; Majello B
    Oncotarget; 2017 Jan; 8(3):3854-3869. PubMed ID: 27894074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
    Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
    Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
    Manohar CF; Salwen HR; Brodeur GM; Cohn SL
    Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of MYCN-amplificated neuroblastoma.
    Zhou Y; Yan H; Zhou Q; Wang P; Yang F; Yuan Z; Du Q; Zhai B
    Clin Transl Med; 2023 Jul; 13(7):e1328. PubMed ID: 37461251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
    Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
    Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells.
    Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M
    BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
    Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.